北京大学学报(医学版) ›› 2018, Vol. 50 ›› Issue (6): 981-985. doi: 10.19723/j.issn.1671-167X.2018.06.007
Meng-ke LIU1,2,3,Lu-chen WANG1,2,3,Fan-lei HU1,2,△()
摘要:
目的: 研究血清基质金属蛋白酶3(matrix metalloproteinase 3,MMP3)在C-反应蛋白(C-reaction protein,CRP)和/或红细胞沉降率(erythrocyte sedimentation rate,ESR)正常的早期类风湿关节炎(early rheumatoid arthritis,ERA)患者中的表达及在病情评估中的意义。方法: 选择北京大学人民医院2011年至2015年确诊的早期RA患者133例,骨关节炎(osteoarthritis,OA)患者25例,健康对照组60例,其中早期RA患者根据CRP、ESR水平分为4组,CRP升高ESR升高组88例,CRP正常ESR正常组15例,CRP正常ESR升高组17例,CRP升高ESR正常组13例,回顾患者临床资料,并采用酶联免疫吸附试验(enzyme linked immunosorbent assay,ELISA)法测定患者及健康对照血清中MMP3水平。结果: CRP正常和/或 ESR正常患者血清MMP3水平[(72.89±6.34) μg/L]明显高于OA组MMP3[(42.87±4.14) μg/L](P=0.002)和健康对照组MMP3水平[(31.62±2.88) μg/L](P<0.001), 其中,CRP正常ESR正常患者血清MMP3水平[(47.04±9.64) μg/L]高于健康对照组,差异具有统计学意义(P<0.05), CRP升高ESR正常患者血清MMP3水平[(94.18±9.11) μg/L]和CRP正常ESR升高患者血清MMP3水平[(79.42±10.60) μg/L]均高于OA组和健康对照组,差异有统计学意义(P<0.05)。在CRP正常和/或ESR正常的早期RA患者中,血清MMP3水平与CRP水平呈正相关(r=0.336,P=0.024)。CRP正常和/或 ESR正常患者MMP3阳性率为44.44%,高于CRP阳性率(28.89%)和ESR阳性率(37.78%), 其中CRP正常ESR升高组阳性率52.94%,CRP升高ESR正常组阳性率53.85%。结论: 血清MMP3水平的测定对于CRP和/或ESR正常的病程小于2年的早期类风湿关节炎患者具有辅助评估价值。
中图分类号:
[1] |
Smolen JS, Aletaha D , McInnes IB. Rheumatoid arthritis[J]. Lancet, 2016,388(10055):2023-2038.
doi: 10.1016/S0140-6736(16)30173-8 |
[2] | 葛均波, 徐永健 . 内科学[M]. 8版. 北京: 人民卫生出版社, 2014: 808-814. |
[3] |
Mittal R, Patel AP, Debs LH , et al. Intricate functions of matrix metalloproteinases in physiological and pathological conditions[J]. J Cell Physiol, 2016,231(12):2599-2621.
doi: 10.1002/jcp.25430 pmid: 27187048 |
[4] | 耿学丽, 武英伟, 孙常铭 , 等. 类风湿关节炎患者基质金属蛋白酶-3的检测[J]. 广东医学, 2016,37(4):555-557. |
[5] |
Hiura K, Iwaki-Egawa S, Kawashima T , et al. The diagnostic utility of matrix metalloproteinase-3 and high-sensitivity C-reactive protein for predicting rheumatoid arthritis in anti-cyclic citrullina-ted peptide antibody-negative patients with recent-onset undifferentiated arthritis[J]. Rheumatol Int, 2013,33(9):2309-2314.
doi: 10.1007/s00296-013-2716-1 pmid: 23503938 |
[6] |
马剑达, 王晓莹, 莫颖倩 , 等. 血清基质金属蛋白酶3评价类风湿关节炎患者病情活动的价值[J]. 中华医学杂志, 2015,95(47):3823-3828.
doi: 10.3760/cma.j.issn.0376-2491.2015.47.006 |
[7] |
Lee YC, Hackett J, Frits M , et al. Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia[J]. Rheumatology (Oxford), 2016,55(4):640-648.
doi: 10.1093/rheumatology/kev388 pmid: 4795537 |
[8] | Ma JD, Wei XN, Zheng DH , et al. Continuously elevated serum matrix metalloproteinase-3 for 3-6 months predict one-year radiographic progression inrheumatoid arthritis: a prospective cohort study[J]. Arthritis Res Ther, 2015,14(17):289-302. |
[9] | Ainola MM, Mandelin JA, Liljestrom MP , et al. Pannus invasionand cartilage degradation in rheumatoid arthritis: involvement of MMP-3 and interleukin-1β[J]. Clin Exp Rheumatol, 2005,23(5):644-650. |
[10] |
Takeshita M, Kuno A, Suzuki K , et al. Alteration of matrix metalloproteinase-3O-glycan structure as a biomarker fordisease activity of rheumatoid arthritis[J]. Arthritis Res Ther, 2016,18(1):112-121.
doi: 10.1186/s13075-016-1013-2 pmid: 4875599 |
[11] |
Houseman M, Potter C, Marshall N , et al. Baseline serum MMP-3 levels in patients with rheumatoid arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up[J]. Arthritis Res Ther, 2012,14(1):30-36.
doi: 10.1186/ar3734 pmid: 3392825 |
[12] |
Shiozawa K, Yamane T, Murata M , et al. MMP-3 as a predictor for structural remission in RA patients treated with MTX mono-therapy[J]. Arthritis Res Ther, 2016,18(1):55-64.
doi: 10.1186/s13075-016-0948-7 pmid: 4769545 |
[13] |
Urata Y, Uesato R, Tanaka D , et al. Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 study[J]. Ann Rheum Dis, 2012,71(4):534-540.
doi: 10.1136/annrheumdis-2011-200108 pmid: 22021897 |
[14] |
孔卓, 吴俊, 张海文 , 等. 血清基质金属蛋白酶3与类风湿关节炎的相关性研究[J]. 标记免疫分析与临床, 2014,21(6):636-639.
doi: 10.11748/bjmy.issn.1006-1703.2014.06.004 |
[15] | 李立新, 蔡蓓, 廖竞宇 , 等. 血清基质金属蛋白酶3对类风湿性关节炎患者骨关节损伤和疗效评估的价值[J]. 细胞与分子免疫学杂志, 2013,29(9):966-969 |
[16] | 史睿, 韩玲, 陈慕芝 , 等. MMP-3、TIMP-1及HCgp-39在早期RA患者血清中的变化及意义[J]. 检验医学与临床, 2017,14(3):325-327. |
[1] | 胥佳佳,王燕,孙贺,贾汝琳,张学武,孟洋,任丽丽,孙晓麟. 可溶性白细胞介素2受体α链的检测与类风湿关节炎疾病活动性评估[J]. 北京大学学报(医学版), 2018, 50(6): 975-980. |
[2] | 张春雨, 刘丽丽, 廖莹, 杜军保, 金红芳. 血浆前白蛋白联合C-反应蛋白对川崎病患儿冠状动脉病变的预测[J]. 北京大学学报(医学版), 2013, 45(2): 207-. |
|